Boston Scientific announced yesterday that it’s halting sales of its implantable cardioverter defibrillators (ICDs). The suspension was due to filing errors and not safety issues, but the company says it still has no idea how long the suspension will last. For a firm fighting to recover back to former glory, this is another setback.
Yet, the stock’s price chart suggests that bottom feeding might not be a bad idea one of these weeks. The news is bad, true, but the news around cheap stocks usually is bad. I watched the stock fall from $45 in 2004, patiently waited for some kind of base to show up, then built a position in 2007 and 2008 at a cost basis of $12.98. Boy, did that look cheap.
It closed yesterday at $6.80.
The stock chart will show you a price line descending at a 45-degree angle for the past five years or so. Notice, however, that even during the financial crisis, the shares bottomed in the $6-7 price band in the November 2008 to March 2009 time frame. Guess from where they bottomed before launching their 42-month 600% shot higher in November 2000? The $6-7 price band. Look where they are again now: the $6-7 price band.
Everybody hates the company, and the stock. The last time I saw people hating it this much was…autumn of 2000. I know there are challenges, yesterday’s headline couldn’t make that clearer, but the company’s new CEO, Ray Elliott, did a good job at Zimmer.
Very good, actually. During his time at Zimmer’s helm, the company’s sales and market capitalization quadrupled. Sales increased from about $1 billion in 1997 to about $4 billion in 2007. He helped take Zimmer public in 2001, with an initial market capitalization of some $5 billion. When he left the firm in 2007, its market capitalization was more than $20 billion. In 2005 he was named “Best CEO in America” for Health Care (Medical Supplies and Devices), by Institutional Investor magazine. He’s no slouch, and he’s the guy in charge of getting Boston back on track.
He bought 100,000 shares of BSX last August for $11 each. Few people felt the pain of yesterday’s news worse than he did. Has he succeeded yet? Not by a long shot. Better news is probably a couple or more quarters away. Still, those bad quarters are looking pretty well accounted for in the stock price these days, and the current price range has proven to be a profitable entry point in the past.
Disclosure: own BSX at $12.98
Look insideThe Kelly Letter
Your email is never published nor shared. Required fields are marked *
You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>
Here are your three options:
Option 1: Annual Subscription
For just $236.97 per year, you’ll receive everything listed above to completely upgrade the way you manage your investments, including a copy of The 3% Signal. This is what I recommend:
Option 2:Monthly Subscription
If you'd like to try The Kelly Letter without paying the full year, you can pay $19.97 per month, but it will not include a copy of The 3% Signal :
Option 3:Free Email List
If you'd like to hear more from me but aren't ready to part with any money yet, you're welcome to join my free email list:
Join Matt and thousands of other rational investors to invest without stress.
Subscribe to The Kelly Letter now!